Company Description
Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions.
Its lead product candidate is TP-03, a novel therapeutic that is in Phase III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.
The company is also developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction.
In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other diseases.
Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.
| Country | United States |
| IPO Date | Oct 16, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 244 |
| CEO | Dr. Bobak R. Azamian M.D. |
Contact Details
Address: 15440 Laguna Canyon Road Irvine, California United States | |
| Website | https://www.tarsusrx.com |
Stock Details
| Ticker Symbol | TARS |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001819790 |
| CUSIP Number | 87650L103 |
| ISIN Number | US87650L1035 |
| Employer ID | 81-4717861 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Bobak R. Azamian M.D. | Co-Founder, President, Chief Executive Officer & Chairman |
| Dr. Seshadri Neervannan Ph.D. | Chief Operating Officer |
| Jeffrey S. Farrow CPA | Chief Financial Officer & Chief Strategy Officer |
| Adrienne Kemp | Senior Director of Corporate Communications |
| David Nakasone | Head of Investor Relations |
| Dianne C. Whitfield M.S.W. | Chief Human Resources Officer |
| Dr. Bryan Wahl J.D., M.D. | General Counsel & Corporate Secretary |
| Dr. Elizabeth Yeu M.D. | Chief Medical Officer |
| Matthew Rossen M.B.A. | Vice President of Marketing |
| Scott Youmans | Vice President of Sales |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 15, 2024 | 4 | Filing |
| Nov 15, 2024 | 3 | Filing |
| Nov 14, 2024 | SC 13G | Statement of acquisition of beneficial ownership b... |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 13, 2024 | 10-Q | Quarterly Report |
| Nov 13, 2024 | 8-K | Current Report |
| Nov 12, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 12, 2024 | SC 13G | Statement of acquisition of beneficial ownership b... |
| Nov 08, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |